PubRank

U Spengler

Author PubWeight™ 122.40‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991 2.38
2 Surface expression and cytolytic function of natural killer cell receptors is altered in chronic hepatitis C. Gut 2005 1.99
3 Long term outcome after transjugular intrahepatic portosystemic stent-shunt in non-transplant cirrhotics with hepatorenal syndrome: a phase II study. Gut 2000 1.89
4 T- and B-cell responses to different hepatitis C virus antigens in patients with chronic hepatitis C infection and in healthy anti-hepatitis C virus--positive blood donors without viremia. Hepatology 1996 1.88
5 [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol 2010 1.76
6 Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol 1991 1.76
7 Activation of a heterogeneous hepatitis B (HB) core and e antigen-specific CD4+ T-cell population during seroconversion to anti-HBe and anti-HBs in hepatitis B virus infection. J Virol 1995 1.71
8 Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest 1999 1.68
9 Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol 2011 1.62
10 Low-molecular weight proteins as markers for glomerular filtration rate. Clin Chem 2001 1.50
11 Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology 2000 1.49
12 [Fatty liver and increased serum lactate in a woman with HIV]. Dtsch Med Wochenschr 2003 1.44
13 Platelet function, thromboxane formation and blood pressure control during supplementation of the Western diet with cod liver oil. Circulation 1983 1.42
14 Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Biomed Pharmacother 1999 1.33
15 Mixed-strain infection with a drug-sensitive and multidrug-resistant strain of Mycobacterium tuberculosis. Lancet 1995 1.32
16 Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C. J Hepatol 1999 1.20
17 Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992 1.19
18 Hepatic levels of bile acids in end-stage chronic cholestatic liver disease. Clin Chim Acta 1996 1.18
19 Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006 1.17
20 [Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C]. Z Gastroenterol 2012 1.17
21 Correlation of serum concentrations of cystatin C and creatinine to inulin clearance in liver cirrhosis. Clin Chem 2000 1.13
22 Hepatitis after chronic abuse of senna. Lancet 1991 1.13
23 Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996 1.10
24 Influence of protease inhibitor therapy on lipoprotein metabolism. J Intern Med 1999 1.08
25 CD30 induction and cytokine profiles in hepatitis C virus core-specific peripheral blood T lymphocytes. J Immunol 1997 1.08
26 Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat 2005 1.07
27 "Atypical p-ANCA" in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000 1.06
28 Enhanced expression of CD80 (B7-1), CD86 (B7-2), and CD40 and their ligands CD28 and CD154 in fulminant hepatic failure. Am J Pathol 1999 1.06
29 Sodium selenite and N-acetylcysteine in antiretroviral-naive HIV-1-infected patients: a randomized, controlled pilot study. Eur J Clin Invest 1998 1.02
30 Serum selenium, plasma glutathione (GSH) and erythrocyte glutathione peroxidase (GSH-Px)-levels in asymptomatic versus symptomatic human immunodeficiency virus-1 (HIV-1)-infection. Eur J Clin Nutr 1997 1.01
31 T(H)1 to T(H)2 shift of cytokines in peripheral blood of HIV-infected patients is detectable by reverse transcriptase polymerase chain reaction but not by enzyme-linked immunosorbent assay under nonstimulated conditions. J Acquir Immune Defic Syndr 2000 1.00
32 Serum selenium versus lymphocyte subsets and markers of disease progression and inflammatory response in human immunodeficiency virus-1 infection. Biol Trace Elem Res 1997 0.97
33 Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol 1998 0.97
34 Interferon/antioxidant combination therapy for chronic hepatitis C--a controlled pilot trial. Antiviral Res 1999 0.96
35 Inadequate erythropoietin response to anaemia in HIV patients: relationship to serum levels of tumour necrosis factor-alpha, interleukin-6 and their soluble receptors. Br J Haematol 1997 0.96
36 Targeting of hepatitis C virus core protein for MHC I or MHC II presentation does not enhance induction of immune responses to DNA vaccination. DNA Cell Biol 1999 0.95
37 Atypical antineutrophil cytoplasmic antibodies with perinuclear fluorescence in chronic inflammatory bowel diseases and hepatobiliary disorders colocalize with nuclear lamina proteins. Hepatology 1998 0.95
38 Natural cytotoxicity and antibody-dependent cellular cytotoxicity (ADCC) is not impaired in patients suffering from chronic hepatitis C. J Hepatol 2001 0.94
39 Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology 1999 0.94
40 Semi-quantification of human C-C chemokine mRNAs with reverse transcription/real-time PCR using multi-specific standards. J Immunol Methods 2000 0.92
41 Differentiation of antineutrophil nuclear antibodies in inflammatory bowel and autoimmune liver diseases from antineutrophil cytoplasmic antibodies (p-ANCA) using immunofluorescence microscopy. Clin Exp Immunol 2001 0.91
42 The IL-1 system in HIV infection: peripheral concentrations of IL-1beta, IL-1 receptor antagonist and soluble IL-1 receptor type II. Clin Exp Immunol 1997 0.91
43 Prediction of imminent complications in HIV-1-infected patients by markers of lymphocyte apoptosis. J Acquir Immune Defic Syndr 2000 0.90
44 Semiquantitative analysis of intrahepatic cytokine mRNAs in chronic hepatitis C. J Infect Dis 1997 0.90
45 Cholestasis associated with mesalazine therapy in a patient with Crohn's disease. J Hepatol 1997 0.89
46 Is the increase in serum cystathionine levels in patients with liver cirrhosis a consequence of impaired homocysteine transsulfuration at the level of gamma-cystathionase? Scand J Gastroenterol 2000 0.89
47 The CCR5Delta32 allele is associated with reduced liver inflammation in hepatitis C virus infection. Eur J Immunogenet 2004 0.89
48 Detection of human aspartyl (asparaginyl) beta-hydroxylase and homeobox B7 mRNA in brush cytology specimens from patients with bile duct cancer. Endoscopy 2006 0.89
49 Immune response of peripheral blood mononuclear cells to HBx-antigen of hepatitis B virus. Hepatology 1991 0.89
50 Liver histopathology in patients with concurrent chronic hepatitis C and HIV infection. Virchows Arch 1997 0.88
51 Isolated tuberculosis of the pancreas masquerading as a pancreatic mass. Am J Gastroenterol 1995 0.88
52 The low-dose monoethylglycinexylidide test: assessment of liver function with fewer side effects. Hepatology 1997 0.87
53 Human immunodeficiency virus and hepatitis C virus coinfection. Eur J Med Res 1998 0.87
54 E-cadherin expression is homogeneously reduced in adenoma from patients with familial adenomatous polyposis: an immunohistochemical study of E-cadherin, beta-catenin and cyclooxygenase-2 expression. Int J Colorectal Dis 2004 0.87
55 Plasmid DNA expressing a secreted or a nonsecreted form of hepatitis C virus nucleocapsid: comparative studies of antibody and T-helper responses following genetic immunization. DNA Cell Biol 1997 0.87
56 Intrahepatic mRNA levels of interferon gamma and tumor necrosis factor alpha and response to antiviral treatment of chronic hepatitis C. J Hum Virol 2001 0.86
57 The tandem-repeat polymorphism of the DC-SIGNR gene in HCV infection. J Viral Hepat 2006 0.86
58 Diagnostic accuracy of atypical p-ANCA in autoimmune hepatitis using ROC- and multivariate regression analysis. Eur J Med Res 2004 0.85
59 Hepatitis C virus core protein does not inhibit apoptosis in human hepatoma cells. Eur J Clin Invest 1999 0.85
60 [Progress of acute liver failure and indications for liver transplantation]. Dtsch Med Wochenschr 1998 0.85
61 Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease. Hepatology 1992 0.85
62 Amanita phalloides intoxications in a family of russian immigrants. Case reports and review of the literature with a focus on orthotopic liver transplantation. Z Gastroenterol 1994 0.85
63 Semiquantitation of human chemokine mRNA levels with a newly constructed multispecific competitor fragment. J Immunol Methods 1999 0.85
64 IgA class antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis and autoimmune hepatitis. Clin Exp Immunol 2003 0.85
65 Antigen-specific cytokine response to hepatitis C virus core epitopes in HIV/hepatitis C virus-coinfected patients. AIDS 1999 0.83
66 Binding of HCV E2 to CD81 induces RANTES secretion and internalization of CC chemokine receptor 5. J Viral Hepat 2004 0.83
67 Intrahepatic expression of interleukin-1beta and tumor necrosis factor-alpha in chronic hepatitis C. J Infect Dis 1999 0.82
68 A hepatitis C virus (HCV) core protein derived peptide inhibits HCV specific lymphocyte proliferation. Eur J Med Res 2000 0.82
69 The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans. Br J Clin Pharmacol 1998 0.82
70 Renal impairment after liver transplantation - a pilot trial of calcineurin inhibitor-free vs. calcineurin inhibitor sparing immunosuppression in patients with mildly impaired renal function after liver transplantation. Eur J Med Res 2009 0.82
71 Autoimmune hepatitis--sequel of a relapsing hepatitis A in a 75-year-old woman. Digestion 2004 0.81
72 Renal functional reserve and nitric oxide in patients with compensated liver cirrhosis. Hepatology 1997 0.81
73 Keratin 18 provides resistance to Fas-mediated liver failure in mice. Eur J Clin Invest 2009 0.81
74 Low diacylglycerol values in colonic adenomas and colorectal cancer. Gut 1990 0.80
75 Splenic abscesses and abdominal tuberculosis in patients with AIDS. Z Gastroenterol 1996 0.80
76 Contractile hyporesponsiveness of hepatic arteries in humans with cirrhosis: evidence for a receptor-specific mechanism. Hepatology 2001 0.80
77 Improvement of sarcoidosis under therapy with interferon-alpha 2b for chronic hepatitis B virus infection. J Hepatol 1999 0.80
78 Flow cytometric analysis of peptide binding to major histocampatibility complex class I for hepatitis C virus core T-cell epitopes. Cytometry 2000 0.80
79 Plasma antioxidant capacity of HIV-seropositive and healthy subjects during long-term ingestion of fruit juices or a fruit-vegetable-concentrate containing antioxidant polyphenols. Eur J Clin Nutr 2001 0.80
80 Challenges and controversies in haemophilia care in adulthood. Haemophilia 2009 0.80
81 Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: a prospective randomized double-blinded multicentre trial. J Viral Hepat 2013 0.79
82 Formation of iso-ursodeoxycholic acid during administration of ursodeoxycholic acid in man. J Hepatol 1991 0.79
83 Intrahepatic MxA expression is correlated with interferon-alpha expression in chronic and fulminant hepatitis. J Pathol 2001 0.79
84 Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin. Infection 2013 0.79
85 The combination of interleukin-2 and interferon alpha effectively augments the antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2 against the colorectal carcinoma cell line HT29. Cancer Immunol Immunother 1998 0.79
86 Deterioration of cholestasis after endoscopic retrograde cholangiography in advanced primary sclerosing cholangitis. J Hepatol 1992 0.79
87 Protein levels of interleukin-12 p70 holomer, its p40 chain and interferon-gamma during advancing HIV infection. J Infect 1998 0.79
88 Nitrite and nitrate levels in patients with cirrhosis of the liver: influence of kidney function and fasting state. Scand J Gastroenterol 1999 0.79
89 Failure of double protease inhibitor therapy as a salvage therapy for HIV-infected patients resistant to conventional triple therapy. Eur J Med Res 1999 0.79
90 Overweight HIV patients with abdominal fat distribution treated with protease inhibitors are at high risk for abnormalities in glucose metabolism - a reason for glycemic control. Eur J Med Res 2008 0.78
91 Elevated soluble tumour necrosis factor receptor serum concentrations and short-term mortality in liver cirrhosis without acute infections. Digestion 2000 0.78
92 Relationship between cytochrome P-450 induction by rifampicin, hepatic volume and portal blood flow in man. Eur J Gastroenterol Hepatol 1997 0.78
93 CCR5-Δ32 genotype does not improve predictive value of IL28B polymorphisms for treatment response in chronic HCV infection. Genes Immun 2013 0.78
94 Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C. Z Gastroenterol 1999 0.78
95 Somatic hypermutation and mRNA expression levels of the BCL-6 gene in patients with hepatitis C virus-associated lymphoproliferative diseases. J Viral Hepat 2007 0.78
96 Increased frequency of CD8+ CD45R0+ memory T lymphocytes in acute hepatitis B virus infection. J Hepatol 1993 0.78
97 Clonal analysis of liver-derived T cells of patients with primary biliary cirrhosis. Clin Exp Immunol 1989 0.78
98 Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C. Digestion 2000 0.78
99 Effect of cytochrome P450 induction on phosphorus metabolites and proton relaxation times measured by in vivo 31P-magnetic resonance spectroscopy and 1H-magnetic resonance relaxometry in human liver. Hepatology 1997 0.78
100 [Liver cirrhosis as precancerous conditions]. Internist (Berl) 1997 0.78
101 [Occurrence and significance of autoantibodies in the course of interferon therapy of chronic hepatitis C]. Dtsch Med Wochenschr 1996 0.78
102 Enhancement of antibody dependent cellular cytotoxicity (ADCC) by combination of cytokines. Hybridoma 1999 0.78
103 Changes of lymphocyte apoptosis associated with sequential introduction of highly active antiretroviral therapy. HIV Med 2003 0.77
104 Lipidation of T helper sequences from hepatitis C virus core significantly enhances T-cell activity in vitro. Immunology 2001 0.77
105 Semiquantitation of intrahepatic MDR3 mRNA levels by reverse transcription/competitive polymerase chain reaction. J Hepatol 1997 0.77
106 Orthotopic liver transplantation in human-immunodeficiency-virus-positive patients in Germany. AIDS Res Treat 2012 0.77
107 Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferon alpha alone in previously untreated patients with chronic hepatitis C: a randomized multicenter trial. Liver 2000 0.77
108 Course and therapy of acute liver failure. Eur J Med Res 2008 0.77
109 Allelic variation in the TNF-beta gene does not explain the low TNF-beta response in patients with primary biliary cirrhosis. Scand J Immunol 1991 0.77
110 [Progressive multifocal leukoencephalopathy]. Med Klin (Munich) 1999 0.77
111 Correlation of transient elastography with APRI and FIB-4 in a cohort of patients with congenital bleeding disorders and HCV or HIV/HCV coinfection. Haemophilia 2010 0.77
112 Vitamin E status in patients with liver cirrhosis: normal or deficient? Metabolism 1999 0.77
113 Augmentation of 17-1A-induced antibody-dependent cellular cytotoxicity by the triple cytokine combination of interferon-alpha, interleukin-2, and interleukin-12. J Immunother 2000 0.77
114 Which lidocaine dose should be used for the MEGX liver function test? J Hepatol 1995 0.77
115 Antiretroviral triple therapy decreases HIV viral load but does not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophiliacs. AIDS 1998 0.77
116 Combinations of the cytokines IL-12, IL-2 and IFN-alpha significantly augment whereas the cytokine IL-4 suppresses the cytokine-induced antibody-dependent cellular cytotoxicity of monoclonal antibodies 17-1A and BR55-2. Cytokine 2000 0.77
117 Crohn's disease is frequently complicated by giardiasis. Scand J Gastroenterol 1988 0.77
118 Prestimulation of monocytes by the cytokines GM-CSF or IL-2 enhances the antibody dependent cellular cytotoxicity of monoclonal antibody 17-1A. Z Gastroenterol 2000 0.77
119 A frequent keratin 8 p.L227L polymorphism, but no point mutations in keratin 8 and 18 genes, in patients with various liver disorders. J Med Genet 2004 0.77
120 Successful thrombolysis after prosthetic pulmonary valve obstruction under aspirin monotherapy. Ann Thorac Surg 1997 0.77
121 Portal hypertension is associated with increased mRNA levels of vasopressor G-protein-coupled receptors in human hepatic arteries. Eur J Clin Invest 2003 0.76
122 Gallbladder emptying is an important factor in fragment disappearance after shock wave lithotripsy. J Hepatol 1993 0.76
123 Fatal pneumonia in an AIDS patient coinfected with adenovirus and Pneumocystis carinii. Infection 2000 0.76
124 [Monoethylglycinexylidide (MEGX)-test. A test for the assessment of prognosis before and after liver transplantation]. Dtsch Med Wochenschr 1995 0.76
125 A comparative study of different enzyme immunosorbent assays for human tumor necrosis factor-alpha. J Immunol Methods 1996 0.76
126 Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients. Liver 2001 0.76
127 Gallbladder emptying during high-dose cholecystokinin infusions. Effect in patients with gallstone disease and healthy controls. Scand J Gastroenterol 1995 0.75
128 Which is the hen and which is the egg? Gastroenterology 2000 0.75
129 Renal functional reserve is well maintained in patients with advanced liver cirrhosis and ascites. Scand J Gastroenterol 2002 0.75
130 Unravelling complexity--the scientific basis of genetic predisposition in autoimmune liver disease. J Hepatol 2001 0.75
131 Hepatitis C virus-associated mixed cryoglobulinaemia. Eur J Gastroenterol Hepatol 1997 0.75
132 Management of progressive outer retinal necrosis with cidofovir in a human immunodeficiency virus-infected patient. Clin Infect Dis 1999 0.75
133 Long-term perturbation of pyridine nucleotides in rat liver. Hoppe Seylers Z Physiol Chem 1980 0.75
134 [Clinical aspects and diagnosis of hepatitis C]. Dtsch Med Wochenschr 2000 0.75
135 Partial remission of a newly diagnosed diffuse large B-cell Non-Hodgkin's lymphoma in a hemodialysis patient after administration of immuno-chemotherapy with rituximab-CHOP. Int J Lab Hematol 2007 0.75
136 [Orthotopic liver transplantation in a 33-year-old patient with fulminant hepatitis B and HIV infection]. Dtsch Med Wochenschr 2000 0.75
137 Renal function in the postoperative period after orthotopic liver transplantation. Transplant Proc 1992 0.75
138 [19-year-old patient with fever, diffuse abdominal pain and diarrhea]. Internist (Berl) 1985 0.75
139 [The prevention of Pneumocystis carinii pneumonia in HIV infection]. Dtsch Med Wochenschr 1993 0.75
140 Structured treatment interruptions following immediate initiation of HAART in eight patients with acute HIV-1 seroconversion. Eur J Med Res 2006 0.75
141 Adenovirus-induced liver necrosis in a case of AIDS. Virchows Arch 1997 0.75
142 Endogenous levels of C-C chemokines MIP-1alpha, MIP-1beta, and RANTES do not reflect the disease course in HIV-seropositive individuals. Int J Clin Lab Res 2000 0.75
143 [Mycobacterium avium infection presenting as a mass in the right lung]. Med Klin (Munich) 2000 0.75
144 Virus-like particles in a case of acute hepatitis with human GB virus-C viraemia. Eur J Gastroenterol Hepatol 2001 0.75
145 [Nucleoside induced hepatopathy in HIV patients. Diagnostic value of liver biopsy assessment]. Pathologe 2004 0.75
146 Carcinogenic potential of dichloroacetylene. Dev Toxicol Environ Sci 1980 0.75
147 [Ursodeoxycholic acid in primary biliary cirrhosis. 2: Prospective long-term study of 21 patients]. Fortschr Med 1988 0.75
148 Nephrogenic diabetes insipidus in a patient taking cidofovir. Lancet 1997 0.75
149 [Tuberculosis--current therapeutic concepts]. Dtsch Med Wochenschr 2005 0.75
150 Survival after 131I-labeled lipiodol therapy for hepatocellular carcinoma. A single-center study based on a long-term follow-up. Nuklearmedizin 2014 0.75
151 [Conservative therapy of acute liver failure]. Dtsch Med Wochenschr 1996 0.75
152 [The therapy of viral hepatitis in HIV-infected patients]. Dtsch Med Wochenschr 1995 0.75
153 In vitro cytopathogenicity of the human immunodeficiency virus (HIV)-1 predicts survival in HIV-infected hemophiliacs independent from CD4 cell count. Eur J Med Res 1998 0.75
154 Enteric dysfunction in patients with asymptomatic HIV-infection versus patients with hypoproteinemia/hypalbuminemia and advanced HIV-infection. Eur J Med Res 2002 0.75
155 [Liver cirrhosis--2: Complications and treatment]. Dtsch Med Wochenschr 2001 0.75
156 Lymphocyte proliferation and apoptosis in HIV-seropositive and healthy subjects during long-term ingestion of fruit juices or a fruit-vegetable-concentrate rich in polyphenols and antioxidant vitamins. Eur J Clin Nutr 2004 0.75
157 [Abdominal colic, arthralgia, petechial skin hemorrhage and glomerulonephritis after a subtropical stay]. Internist (Berl) 1990 0.75
158 Indication, outcome and follow up of intensive care in patients with HIV-infection. Eur J Med Res 2000 0.75
159 Changing role of invasive aspergillosis in AIDS--a case control study. J Infect 1998 0.75
160 Transient loss of T-cell reactivity in a patient with hepatitis C virus reinfection. Digestion 2001 0.75
161 [Primary sclerosing cholangitis - challenges for all. The German Study Group PSC]. Z Gastroenterol 2011 0.75
162 Carcinogenicity of dichloroacetylene: an inhalation study. Carcinogenesis 1984 0.75
163 [Painless jaundice and a space-occupying lesion in the liver hilus in a 60-year-old patient]. Internist (Berl) 1986 0.75
164 [Chronic hepatitis C in type-II cryoglobulinemia and cutaneous vasculitis]. Dtsch Med Wochenschr 1994 0.75
165 Mutagenicity of dichloroacetylene and its degradation products trichloroacetyl chloride, trichloroacryloyl chloride and hexachlorobutadiene. Mutat Res 1983 0.75
166 [Do polymorphisms of the SDF1 and CCR2b genes modify the course of hepatitis C or HIV/HCV co-infection?]. Dtsch Med Wochenschr 2002 0.75
167 Hepatic disease. Eur J Gastroenterol Hepatol 1999 0.75
168 [Antineutrophil cytoplasmatic antibodies and their diagnostic significance as serum markers]. Dtsch Med Wochenschr 1999 0.75
169 [Ursodeoxycholic acid in primary biliary cirrhosis. 1: Therapeutic approaches up to now and the rationale for treatment with ursodeoxycholic acid]. Fortschr Med 1988 0.75
170 [HIV-infection: modern antiretroviral therapy]. Dtsch Med Wochenschr 2004 0.75
171 [Diagnosis of acute liver failure]. Dtsch Med Wochenschr 1996 0.75
172 [Hepatitis and posthepatic cirrhosis in AIDS]. Verh Dtsch Ges Pathol 1995 0.75